Rafferty Asset Management
RCKT icon

Rafferty Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Rafferty Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-141,212
Closed -$506K – 1160
2026
Q1 		$506K Buy
+141,212
New +$561K ﹤0.01% 890
2025
Q2 		– Sell
-155,875
Closed -$1.04M – 1100
2025
Q1 		$1.04M Sell
155,875
-385
-0.2% -$3.8K ﹤0.01% 733
2024
Q4 		$1.96M Buy
156,260
+27,534
+21% +$414K 0.01% 652
2024
Q3 		$2.38M Buy
128,726
+11,081
+9% +$227K 0.01% 588
2024
Q2 		$2.53M Sell
117,645
-211,398
-64% -$4.86M 0.01% 580
2024
Q1 		$8.86M Buy
329,043
+120,538
+58% +$3.42M 0.03% 313
2023
Q4 		$6.25M Sell
208,505
-33,137
-14% -$731K 0.03% 393
2023
Q3 		$4.95M Buy
241,642
+8,558
+4% +$156K 0.03% 388
2023
Q2 		$4.63M Sell
233,084
-66,375
-22% -$1.34M 0.03% 433
2023
Q1 		$5.13M Buy
299,459
+5,498
+2% +$108K 0.03% 378
2022
Q4 		$5.75M Buy
293,961
+67,443
+30% +$1.24M 0.05% 346
2022
Q3 		$3.62M Buy
226,518
+139,896
+162% +$2.18M 0.04% 387
2022
Q2 		$1.19M Sell
86,622
-78,651
-48% -$938K 0.01% 588
2022
Q1 		$2.62M Buy
165,273
+20,866
+14% +$360K 0.02% 535
2021
Q4 		$3.15M Buy
144,407
+56,213
+64% +$1.53M 0.02% 525
2021
Q3 		$2.64M Buy
88,194
+31,707
+56% +$1.15M 0.02% 548
2021
Q2 		$2.5M Sell
56,487
-5,646
-9% -$245K 0.02% 598
2021
Q1 		$2.76M Buy
62,133
+55,163
+791% +$3.03M 0.02% 541
2020
Q4 		$382K Sell
6,970
-29,852
-81% -$1.09M ﹤0.01% 748
2020
Q3 		$842K Buy
36,822
+21,975
+148% +$541K 0.01% 599
2020
Q2 		$311K Buy
+14,847
New +$268K ﹤0.01% 819
2020
Q1 		– Sell
-15,783
Closed -$359K – 761
2019
Q4 		$359K Sell
15,783
-25,198
-61% -$421K 0.01% 753
2019
Q3 		$477K Sell
40,981
-3,734
-8% -$46.3K 0.01% 668
2019
Q2 		$671K Buy
44,715
+13,792
+45% +$241K 0.01% 635
2019
Q1 		$542K Buy
+30,923
New +$488K 0.01% 654

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Rafferty Asset Management's RCKT Position: Q2 2026 in Review

Rafferty Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 141,212 shares — an estimated $506K sold.

Rafferty Asset Management first reported a position in RCKT in Q1 2019 and held it in 25 quarters. The position peaked at $8.86M in Q1 2024. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Rafferty Asset Management reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 141,212 Rocket Pharmaceuticals shares in Q2 2026, an estimated $506K.
  • Rafferty Asset Management first reported a position in Rocket Pharmaceuticals in Q1 2019 and held it in 25 quarters.
  • Rafferty Asset Management's Rocket Pharmaceuticals position peaked at $8.86M in Q1 2024.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.